Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Chronic Hepatitis B
- Registration Number
- NCT00048945
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 820
Inclusion Criteria
- Clinical diagnosis of hepatitis B
- Not pregnant
Exclusion Criteria
- Treatment for hepatitis B in past 6 months
- Other hepatitis infections
- Severe liver disease
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method